Register  /  Login               
Print this article
- 11/20/2020

Lonza Expands Highly Potent Drug Product Development and Manufacturing Capabilities

Chimica Oggi-Chemistry Today

Lonza has announced additional investments in its oral drug product development and manufacturing capabilities at its Tampa FL site. Capability for formulation development has been enhanced with the upgrade of drug product development laboratories for highly potent material handling. Dry granulation processing has been expanded and standardized with the addition of Gerteis roller compaction equipment. The new roller compactor will be equipped with high containment and adds to Lonza’s integrated highly potent API (HPAPI) value chain across drug substance, particle engineering and specialized drug product.


The containment capability of the new roller compaction unit complements Lonza’s leading capabilities in HPAPI processing across its site network in the US and Europe. The Visp, Switzerland site has one of the world’s largest capacity for HPAPI development and manufacturing. Contained particle engineering, using either jet milling or spray dry processing, and specialized oral solid or parenteral drug product capabilities are also available within the network.


Lonza has invested more than $15M to expand and upgrade the Tampa site capabilities over the last two years. The new roller compaction equipment complements previously made HPAPI processing investments inclusive of a new sampling and dispensing suite, a dedicated suite for product development, and two new product manufacturing suites.

About us

tks | publisher, event organiser,
media agency

Viale Brianza, 22
20127 - Milano - Italy
Tel. +39 02 26809375